Inceptua Group Selected to Manage TikoMed’s Named Patient Program for Investigational Therapy ILB® in Amyotrophic Lateral Sclerosis (ALS)
Windsor, London, UK, 26th August 2026 – Life Science Newswire – Inceptua Group (Inceptua) and TikoMed AB (TikoMed) have announced the launch of a Named Patient Program for TikoMed’s investigational drug, ILB®, for eligible patients with Amyotrophic Lateral Sclerosis (ALS).
ALS, also known as Lou Gehrig's disease, is a progressive, fatal neurodegenerative disorder. It progressively damages motor neurons in the brain and spinal cord, leading to severe muscle weakness, loss of voluntary movement, and eventually respiratory failure. ALS is a rare disease affecting about 2-3 in every 100,000 individuals worldwide. There is currently no cure for ALS.
A Named Patient Programme is a compliant way for medicines that are not approved in their country of intended use to be made available for patients who either have no alternative treatment option or have exhausted all other treatment options available in their country of residence. The ILB® Named Patient Program is designed to provide eligible patients with a pathway to access ILB® prior to regulatory approval, where permitted under local regulations.
Stuart Bell, Executive Vice President, Inceptua Early Access said, “Inceptua is proud to support TikoMed in making its investigational product, ILB®, available whilst it is still going through the clinical trial development process. Patients with ALS have very limited treatment options.”
Björn Pilström, CEO and CMO of TikoMed said, “TikoMed is happy to collaborate with Inceptua on this programme to help support access to ILB® for eligible patients with no alternative treatments for a life-threatening disease. Inceptua has a long and proven track record of providing Named Patient Programmes for the pharmaceutical industry and we are confident this collaboration will help provide an important access pathway for eligible patients across the globe.”.
Requests for access to ILB® must be made by a Healthcare Professional (HCP). HCPs can request access for a patient by contacting Inceptua at: access@inceptua.com or calling + 44 20 3910 7670.
ALS, also known as Lou Gehrig's disease, is a progressive, fatal neurodegenerative disorder. It progressively damages motor neurons in the brain and spinal cord, leading to severe muscle weakness, loss of voluntary movement, and eventually respiratory failure. ALS is a rare disease affecting about 2-3 in every 100,000 individuals worldwide. There is currently no cure for ALS.
A Named Patient Programme is a compliant way for medicines that are not approved in their country of intended use to be made available for patients who either have no alternative treatment option or have exhausted all other treatment options available in their country of residence. The ILB® Named Patient Program is designed to provide eligible patients with a pathway to access ILB® prior to regulatory approval, where permitted under local regulations.
Stuart Bell, Executive Vice President, Inceptua Early Access said, “Inceptua is proud to support TikoMed in making its investigational product, ILB®, available whilst it is still going through the clinical trial development process. Patients with ALS have very limited treatment options.”
Björn Pilström, CEO and CMO of TikoMed said, “TikoMed is happy to collaborate with Inceptua on this programme to help support access to ILB® for eligible patients with no alternative treatments for a life-threatening disease. Inceptua has a long and proven track record of providing Named Patient Programmes for the pharmaceutical industry and we are confident this collaboration will help provide an important access pathway for eligible patients across the globe.”.
Requests for access to ILB® must be made by a Healthcare Professional (HCP). HCPs can request access for a patient by contacting Inceptua at: access@inceptua.com or calling + 44 20 3910 7670.